Figure 6.
High concentrations of a metabolically active folate derivative rescue methotrexate toxicity. (A-B) Dose-response curves for NALM-6 (A) and Jurkat (B) leukemia cells treated with different concentrations of the folate derivative 5-MTHF in either the absence or presence of methotrexate. Leukemia cell viability was assessed after 48 hours of drug treatment using the CellTiter-Glo luminescent cell viability assay. Error bars represent the mean ± SD of 3 technical replicates. (C-F) Methotrexate dose-response curves for NALM-6 (C,E) and Jurkat (D,F) leukemia cells in either the absence or presence of 5-MTHF 100 nM in either regular media (C-D; RPMI 1640 and 10% FBS) or folate-free media (E-F; folate-free RPMI 1640 and dialyzed 10 % FBS). Leukemia cell viability was assessed after 48 hours of drug treatment using the CellTiter-Glo luminescent cell viability assay. Error bars represent the mean ± SD of 3 technical replicates.

High concentrations of a metabolically active folate derivative rescue methotrexate toxicity. (A-B) Dose-response curves for NALM-6 (A) and Jurkat (B) leukemia cells treated with different concentrations of the folate derivative 5-MTHF in either the absence or presence of methotrexate. Leukemia cell viability was assessed after 48 hours of drug treatment using the CellTiter-Glo luminescent cell viability assay. Error bars represent the mean ± SD of 3 technical replicates. (C-F) Methotrexate dose-response curves for NALM-6 (C,E) and Jurkat (D,F) leukemia cells in either the absence or presence of 5-MTHF 100 nM in either regular media (C-D; RPMI 1640 and 10% FBS) or folate-free media (E-F; folate-free RPMI 1640 and dialyzed 10 % FBS). Leukemia cell viability was assessed after 48 hours of drug treatment using the CellTiter-Glo luminescent cell viability assay. Error bars represent the mean ± SD of 3 technical replicates.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal